Medicare beneficiaries pay $50/month copay
Who Should Not Use These Compounds and What Are the Key Risks Neither retatrutide nor tirzepatide is appropriate for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), based on preclinical signals observed across the GLP-1 receptor agonist class
Peptide therapy can benefit a wide range of individuals, from those looking to improve their physical performance to people seeking enhanced overall health and well-being
Appetite suppression is a common side effect of taking these drugs, and it helps lead to weight loss
Week-by-Week Timeline Understanding what to expect, and when to expect it, sets realistic benchmarks and prevents the kind of early dropout that comes from misaligned expectations
At baseline, the population had diabetes for an average of 9 years, had a mean HbA1c of 8.2%, and 30% had established microvascular disease